Search

Displaying results 1751 - 1760 of 10000 in total
  1. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    [L26966,L26976] In November 2021, Health Canada [L39115] and the EMA [L39272] approved the vaccine to be administered as a booster dose approximately six months after the second dose. … [L36025] Currently, sufficient data are not available to determine the longevity of protection against COVID-19, nor direct evidence that the vaccine prevents the transmission of the SARS-CoV-2 virus

  2. Drug

    Estradiol

    go.drugbank.com/drugs/DB00783
    ApprovedInvestigationalVet approved

    [DB00977] (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination oral contraceptive pills (OCPs). … Ethinyl estradiol is different from estradiol due to its higher biovailability and increased resistance to metabolism, rendering it more suitable for oral administration.

    Categories: Sex Hormones and Modulators of the Genital SystemProducts: JUVENUM E, ESTRADERM TTS DE 100 MCG
  3. Drug

    Apazunersen

    go.drugbank.com/drugs/DB16981
    Investigational

    Apazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]

    Categories: Antisense Oligonucleotide Specific to the Antisense Transcript of UBE3A
  4. Drug

    Finasteride

    go.drugbank.com/drugs/DB01216
    ApprovedInvestigational

    Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in … [L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.

  5. Drug

    Filgrastim

    go.drugbank.com/drugs/DB00099
    ApprovedInvestigational

    Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. … [L40773] A long-acting, pegylated G-CSF, [pegfilgrastim], was made available to increase the duration of action of the drug.

    Products: E/0.5ML, E/0.5ML
  6. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence. … Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Aminopterin

    go.drugbank.com/drugs/DB08878
    ApprovedWithdrawn

    Clinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.

  8. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    [A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit drastically reduced metabolic degradation compared to traditional synthetic oligonucleotides. … [A218171, A218176, A218191] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping, which retains a productive reading frame and results in the

  9. Drug

    Chloramphenicol

    go.drugbank.com/drugs/DB00446
    ApprovedInvestigationalVet approvedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this … It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic.

    Products: PALMITATO DE CHLOROMYCETIN
  10. Drug

    Mirtazapine

    go.drugbank.com/drugs/DB00370
    ApprovedInvestigational

    [A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. … [T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-2 Receptor AntagonistsInternational brands: Avanza